Global Life Sciences Solutions USA LLC

Global Life Sciences Solutions USA LLC, a wholly owned subsidiary of Danaher Corporation headquartered in Marlborough, Massachusetts, supplies advanced scientific equipment, laboratory consumables, and specialized maintenance services to federal research institutions as a prime contractor competing on full-and-open federal procurement. The company holds no SBA set-aside designations and competes across civilian federal agencies without small business preferences.

Global Life Sciences Solutions operates as a critical supplier of chromatography systems, surface plasmon resonance instruments, cell processing equipment, controlled-rate freezers, fluorescence imaging systems, and associated consumables and maintenance services to the National Institutes of Health ecosystem and other federal research agencies. Representative prime contract work includes a $40.1 million Other Transaction Agreement with the National Institutes of Health (awarded September 2025) for CRISPR delivery and manufacturing innovation in minimal-cost cancer and HIV therapies via in vivo immune engineering, running through September 2031; a $442.6 million purchase order from the Defense Health Agency (November 2023) for an AKTA READY 450 liquid chromatography system; a $465.1 million firm fixed-price purchase order from the Food and Drug Administration (August 2022) for an XDR-50 single-use bioreactor system with a two-year manufacturer warranty and optional one-year maintenance extensions; and a $1 million purchase order from the NIH Clinical Center (September 2023) for ViaFreeze controlled-rate freezers, ViaThaw dry thawers, and SEPAX C-Pro cell processing systems for the Centers for Cellular Engineering. The company also holds a $72.1 million definitive contract from the Office of the Assistant Secretary for Preparedness and Response (August 2023) for capacity expansion in support of COVID-19 response and public health emergencies, running through December 2038.

Customer concentration sits heavily with the National Institutes of Health ecosystem. The top five customer agencies by award count account for 24 percent of recent awards and include NIH Office of the Director (236 awards, $1.8 million combined potential value), National Cancer Institute (193 awards, $4.6 million), National Institute of Allergy and Infectious Diseases (193 awards, $5 million), NIAID DEA OA Acquisitions (174 awards, $3.1 million), and National Institute of Diabetes and Digestive and Kidney Diseases (135 awards, $2.9 million). When measured by potential value, the top five customers account for 18 percent of combined potential dollars and include NIH broadly (103 awards, $40.9 million), FDA (112 awards, $6.7 million), NIAID (193 awards, $5 million), National Cancer Institute (193 awards, $4.6 million), and the Department of the Army Medical Command (86 awards, $4.1 million). The company serves 124 distinct customer agencies.

Global Life Sciences Solutions holds a $10 million single-award Blanket Purchase Agreement with the National Institutes of Health's Office of Logistics and Acquisition Operations (effective November 29, 2023 through November 30, 2026), enabling multiple NIH institutes to procure biological materials, media, chemicals, laboratory supplies, and medical and scientific equipment through pre-negotiated terms. The company places substantial volume under GSA vehicles: the Federal Supply Schedule GS26F4791A carries 392 task orders worth $9.6 million combined potential value, and the Multiple Award Schedule hosts 148 task orders worth $8.3 million. Additional BPA vehicles include single-award arrangements such as HHSN263200000052400B (112 task orders, $1.1 million) and HHSN263201600055B (101 task orders, $1 million), reflecting the company's dominant presence in NIH procurement infrastructure.

Recent activity shows 16 awards in 2026, 36 in 2025, 55 in 2024, 48 in 2023, and 53 in 2022, indicating relatively stable year-to-year volume after seasonal variation. Twenty awards totaling $1.3 million in combined potential value reach completion within the next twenty-four months, creating recompete exposure in that window. The company's award footprint spans primarily analytical laboratory instrument manufacturing (1,316 awards), equipment repair and maintenance (607 awards), research and development in biotechnology (78 awards), and in-vitro diagnostic substance manufacturing (42 awards) under NAICS classifications. By PSC code, the company concentrates in laboratory equipment and supplies (1,189 awards), maintenance and repair of instruments and laboratory equipment (810 awards), and medical and surgical instruments and supplies (420 awards).

Global Life Sciences Solutions operates as a pure prime contractor, with no documented subcontract role in the source data; the company does hold documented sub-awards where it is the recipient of work from primes including Booz Allen Hamilton, Weems Design Studio, University of California San Diego, Becton Dickinson, and Roche Diagnostics, primarily for chromatography equipment, maintenance agreements, and microfluidic processing systems supporting vaccine research and diagnostic initiatives.